ONCORAL PHARMA ApS: Financial statements 2022
CVR: 35481214
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ONCORAL PHARMA ApS (CVR 35481214) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -7,461,588 and a net result of DKK -9,206,889 compared with DKK -11,818,103 the year before. Equity in the 2022 report amounted to DKK -26,465,045.
- Gross Profit
- DKK -7,461,588
- Profit/Loss
- DKK -9,206,889
- Equity
- DKK -26,465,045
- Total Assets
- DKK 9,597,282
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -7.5 mio. | -9.2 mio. | -26.5 mio. | - |
| 2021 | - | -13.8 mio. | -11.8 mio. | -17.3 mio. | - |
| 2020 | - | -3.9 mio. | -3.5 mio. | -5.4 mio. | - |
| 2019 | - | -1.6 mio. | -1.5 mio. | -1.4 mio. | - |
| 2016 | - | -419 t. | -935 t. | -4.5 mio. | 0 |
Official annual report
Keep an eye on ONCORAL PHARMA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
ONCORAL PHARMA ApS has published its annual report for 2021. Gross profit came to DKK -13,819,766, and the net result was DKK -11,818,103.
About ONCORAL PHARMA ApS
ONCORAL PHARMA ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Magnus Olafsson Corfitzen. The company is owned by Ascelia Pharma AB. The company has 0 employees (2014). In 2025, the company reported a gross profit of DKK -1,617,542 and a net result of DKK -2,313,169 compared with DKK -4,057,834 the year before. Equity in the 2025 report amounted to DKK -35,503,290.